Bank of America set a $67.00 target price on EXACT Sciences (NASDAQ:EXAS) in a research report report published on Monday. The firm currently has a buy rating on the medical research company’s stock.

Several other equities analysts have also commented on the stock. Canaccord Genuity upgraded shares of EXACT Sciences to a buy rating and set a $60.00 price objective for the company in a research report on Tuesday, October 31st. Leerink Swann reiterated an outperform rating and set a $67.00 price objective (up previously from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. Robert W. Baird increased their price objective on shares of EXACT Sciences from $49.00 to $56.00 and gave the company an outperform rating in a research report on Tuesday, October 31st. Jefferies Group increased their price objective on shares of EXACT Sciences to $60.00 and gave the company a buy rating in a research report on Tuesday, October 31st. Finally, Craig Hallum increased their price objective on shares of EXACT Sciences from $46.00 to $61.00 and gave the company a buy rating in a research report on Tuesday, October 31st. Eight research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $50.58.

EXACT Sciences (EXAS) opened at $55.06 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. EXACT Sciences has a 12-month low of $16.95 and a 12-month high of $63.60. The firm has a market cap of $6,590.00, a price-to-earnings ratio of -47.88 and a beta of 0.68.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. During the same quarter in the prior year, the business earned ($0.36) earnings per share. EXACT Sciences’s revenue for the quarter was up 158.4% on a year-over-year basis. analysts expect that EXACT Sciences will post -1.1 EPS for the current year.

In related news, SVP D Scott Coward sold 1,665 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total value of $87,479.10. Following the transaction, the senior vice president now owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Graham Peter Lidgard sold 45,775 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $53.60, for a total transaction of $2,453,540.00. Following the completion of the transaction, the insider now directly owns 272,819 shares in the company, valued at approximately $14,623,098.40. The disclosure for this sale can be found here. In the last three months, insiders sold 610,433 shares of company stock worth $34,341,306. Insiders own 4.00% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Fred Alger Management Inc. purchased a new position in EXACT Sciences during the 2nd quarter valued at about $84,177,000. Lord Abbett & CO. LLC increased its position in EXACT Sciences by 59.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after purchasing an additional 875,527 shares during the period. Vanguard Group Inc. increased its position in EXACT Sciences by 8.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after purchasing an additional 700,051 shares during the period. Green Valley Investors LLC purchased a new position in EXACT Sciences during the 2nd quarter valued at about $20,892,000. Finally, FMR LLC increased its position in EXACT Sciences by 32.7% during the 2nd quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after purchasing an additional 571,796 shares during the period. 82.39% of the stock is currently owned by institutional investors.

WARNING: “Bank of America Reiterates “$67.00” Price Target for EXACT Sciences (EXAS)” was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/01/12/bank-of-america-reiterates-67-00-price-target-for-exact-sciences-exas.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.